Alteogen signs option and license pact with Novartis for Hybrozyme-enabled products
Alteogen entered an option and license agreement with Novartis covering development and commercialization of Hybrozyme™-enabled subcutaneous products.
DAEJEON, South Korea, Sept.
2, 2026 // -- Alteogen Inc. (KOSDAQ: 196170), a leading biopharmaceutical company specializing in platform technologies, announced today that it has entered into an option and license agreement with Novartis for the development and commercialization of subcutan…